Share
“Our specialists will discuss your care together at a tumour-board meeting” may be reassuring, but you may also have questions. Who will attend? Does it mean the cancer is unusually serious? Will treatment be delayed? How will your wishes be included?
An MDT is a multidisciplinary team: healthcare professionals with different areas of expertise working together. At a tumour-board meeting, specialists discuss the diagnosis and treatment options for patients with cancer. They bring their expertise together to recommend a coordinated care plan. Having your care discussed at this meeting does not, by itself, mean that the cancer is advanced or that something has gone wrong.
Why your care may involve several specialists
Cancer treatment can involve removing a tumour, treating an area with radiation, giving medicines that reach different parts of the body, or combining these approaches. The sequence may be as important as each individual treatment.
Consider an illustrative situation: a tumour appears operable but lies close to an important structure. The surgeon assesses whether it can be removed safely; the medical oncologist considers treatment beforehand; the radiation oncologist assesses whether radiation has a role; and the pathologist may identify a feature that changes the medicine choice. These questions are connected.
Deciding them independently can leave a patient with instructions that do not fit together. Multidisciplinary planning considers the complete strategy rather than simply collecting separate recommendations.
Who usually contributes?
Membership varies by cancer and by the question. Not every specialist needs to be involved in each person’s care.
If the table extends beyond your screen, swipe or scroll sideways to read every column.
Team member | What they contribute |
|---|---|
Medical oncologist or haemato-oncologist | Systemic treatment, blood-cancer care, medical fitness and treatment sequencing |
Cancer or organ-specific surgeon | Whether surgery is appropriate, its extent and functional consequences |
Radiation oncologist | Whether radiation can help and how to deliver it safely |
Pathologist | Diagnostic certainty, tissue findings and additional tests needed |
Radiologist or nuclear-medicine specialist | Scan interpretation, disease extent and imaging uncertainties |
Other relevant professionals | Genetics, nursing, nutrition, rehabilitation, palliative care or another specialty when needed |
The formal meeting does not replace the wider care team. Many practical matters, such as nausea control, feeding support and family communication, are addressed through consultations and ongoing coordination outside the board.
What information is reviewed?
A useful presentation includes the diagnosis, pathology, relevant images, prior treatment, symptoms and the decision to be made. The team also needs to understand your overall health, other medical conditions and what matters most to you.
The question might be whether a scan abnormality represents metastatic disease, whether pathology needs review, whether treatment should precede surgery, or whether a biomarker changes the recommended medicine. Sometimes the most useful outcome is to obtain one missing piece of information before committing to treatment.
An impressive meeting cannot compensate for incomplete records. Patients can help by ensuring that reports and images from other hospitals are available and that the presenting doctor knows about the issues most important to them.
What can the discussion change?
An MDT can clarify sequencing, identify a need for additional expertise, resolve uncertainty or confirm an appropriate plan. It may recommend less treatment rather than more.
For example, an uncertain scan finding might need targeted clarification instead of an immediate assumption that the cancer has spread. For another person, the group may explain why medicines or radiation are useful even when the visible tumour can be removed. Conversely, it may conclude that an additional procedure is unlikely to justify its risks.
These are reasons to value coordinated review, but they should not become promises that every meeting improves survival or that a unanimous recommendation is infallible. How helpful the meeting is depends on your individual needs, the available evidence and how the recommendations are put into practice.
Does every patient need a formal meeting?
Multidisciplinary input is especially helpful for treatment involving several modalities, uncommon diagnoses, uncertain stage, recurrence, complex surgery or conflicting advice. Some centres routinely review broad groups of new patients; some straightforward questions are discussed directly between the relevant specialists.
The important point is that sequencing is deliberate. A patient should not receive an operation simply because they happened to see the surgeon first, or a drug simply because they first met the medical oncologist, without considering the appropriate overall pathway.
Ask: “Have the other relevant specialists contributed to my plan?” and “Would a formal tumour-board discussion help with any decisions about my care?” The answer should describe the process, not simply use MDT as a reassuring label.
Will I be in the meeting?
Many tumour boards are meetings between healthcare professionals, so you may not attend in person. Your treating doctor explains your diagnosis, treatment history and priorities to the team, then discusses their recommendations with you afterwards. Arrangements vary between centres.
Whether or not you attend, your priorities should be represented. Tell the team about concerns such as fertility, speech, swallowing, mobility, a stoma, work, travel or responsibilities at home. These may influence the choice between medically reasonable options.
An MDT recommendation does not replace informed consent. You still need an understandable explanation of the expected benefit, important risks and alternatives. You may also want a trusted family member involved, with your permission.
What should happen afterwards?
Ask your doctor to translate the outcome into a plan: what comes first, what is still pending, which specialist you see next and who arranges the next step.
Distinguish a definite recommendation from a conditional one. “Surgery is advised” is different from “Surgery may be appropriate if another test excludes disease elsewhere.” Knowing that condition avoids confusion when further investigation is requested.
A short written summary is valuable, particularly if care takes place across several hospitals. It should identify the recommendation, its rationale, outstanding questions and the clinician coordinating care. What matters is that you and your care team understand the next steps.
What if specialists disagree?
Medicine does not always provide one clearly superior option. Specialists can interpret limited evidence differently or weigh cancer control and side effects differently. Good multidisciplinary care acknowledges uncertainty instead of concealing it.
Ask which part of the decision is uncertain and whether more information could resolve it. Sometimes several approaches are reasonable, and your priorities help guide the choice. A second opinion can help when important uncertainty remains.
You do not have to accept treatment simply because “the board decided”. Equally, a recommendation is not invalid merely because it differs from what you expected. Your team should explain the reasons, listen to your concerns and help you decide on the next steps together.
Could waiting for the board delay necessary care?
Ask when the discussion will happen and whether waiting is safe. A time-limited review can prevent an inappropriate treatment sequence; an avoidable administrative delay is different.
Urgent complications need prompt assessment rather than waiting for the next scheduled meeting. The broader strategy can be discussed once the immediate problem has been addressed.
Frequently asked questions
Is an MDT the same as a second opinion?
No. An MDT integrates expertise within a coordinated treatment process. A second opinion is an additional independent review, often elsewhere. Both can be useful, but they answer different needs.
Does it mean I will need chemotherapy, surgery and radiotherapy?
No. Involving those specialties helps establish which treatments are needed and which are not. Access to every modality is not a reason to use all of them.
Can my care be discussed again later?
Yes. Recurrence, an unexpected response or another major decision may justify further review. Cancer planning is not necessarily a single meeting at diagnosis.
What is the most useful contribution I can make?
Ensure the team knows your symptoms, previous treatment and priorities. A technically appropriate plan must also fit the person who will live with its consequences.
A tumour board matters when its expertise becomes a plan you understand—not merely when several specialists have looked at the same scan.
Medical information notice: This information is for general education and does not replace individual medical advice. Cancer treatment depends on the diagnosis, stage, tumour biology, previous treatment, general health and individual circumstances.
